The Role of Avastin in the Management of Recurrent Glioblastoma

Neurosurgery Clinics of North America

Volumn 23, Issue 2, 2012, Pages 331-341

  Sweet, Jennifer A ^a   Feinberg, Michelle L ^a   Sherman, Jonathan H ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Angiogenic switch; Antiangiogenic; Avastin; Bevacizumab; Radiation necrosis; Recurrent glioblastoma; Treatment malignant glioma; VEGF

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CABOZANTINIB; CARBOPLATIN; CEDIRANIB; CILENGITIDE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; INTEGRIN RECEPTOR; IRINOTECAN; MANNITOL; OXALIPLATIN; PACLITAXEL; PLACEBO; PLACENTAL GROWTH FACTOR; STEROID; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

AMINOTRANSFERASE BLOOD LEVEL; ANTIANGIOGENIC ACTIVITY; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN SURGERY; BREAST CANCER; CANCER INHIBITION; CANCER RADIOTHERAPY; COLORECTAL CANCER; CONVULSION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HEADACHE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; INFECTION; INHIBITION KINETICS; KARNOFSKY PERFORMANCE STATUS; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION NECROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BINDING; RECURRENT CANCER; REVIEW; SEIZURE; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TUMOR VASCULARIZATION; TUMOR VOLUME; WOUND HEALING IMPAIRMENT; WOUND INFECTION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84858592194     PISSN: 10423680     EISSN: 15581349     Source Type: Journal    
DOI: 10.1016/j.nec.2012.02.001     Document Type: Review

References (55)

1. CBTRUS, Hinsdale I.L. Statistical report: primary brain tumors in the United States, 2004-2007 2011, Central Brain Tumor Registry of the United States.
2. Louis D., Ohgaki H., Wiestler O., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114(2):97-109.
3. Stupp R., Mason W., van den Bent M., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987-996.
4. Narayana A., Golfinos J., Fischer I., et al. Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys 2008, 72(2):383-389.
5. Shirai K., Siedow M., Chakravarti A. Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant glioma. J Oncol 2012, 2012:193436.
6. Daumas-Duport C., Scheithauer B., O'Fallon J., et al. Grading of astrocytomas. A simple and reproducible method. Cancer 1988, 62(10):2152-2165.
7. Wong E., Hess K., Gleason M., et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999, 17(8):2572-2578.
8. Onishi M., Ichikawa T., Kurozumi K., et al. Angiogenesis and invasion in glioma. Brain Tumor Pathol 2011, 28(1):13-24.
9. Buie L., Valgus J. Bevacizumab: a treatment option for recurrent glioblastoma multiforme. Ann Pharmacother 2008, 42(10):1486-1490.
10. Jain R., di Tomaso E., Duda D., et al. Angiogenesis in brain tumors. Nat Rev Neurosci 2007, 8(8):610-622.
11. Cohen M., Shen Y., Keegan P., et al. FDA approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009, 14(11):1131-1138.
12. Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 2010, 21(1):21-26.
13. Gerber H., Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005, 65(3):671-680.
14. Presta L., Checn H., O'Connor S., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57(20):4593-4599.
15. Chung A., Ferrara N. Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol 2011, 27:563-584.
16. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285(21):1182-1186.
17. Fine H., Figg W., Jeackle K., et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high grade gliomas. J Clin Oncol 2000, 18(4):708-715.
18. Folkman J. Tumor angiogenesis. Adv Cancer Res 1974, 19(0):331-358.
19. Calabrese C., Poppleton H., Kocak M., et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11(1):69-82.
20. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86(3):353-364.
21. Dayan F., Mazure N., Brahimi-Horn M., et al. A dialogue between the hypoxia-inducible factor and the tumor microenvironment. Cancer Microenviron 2008, 1(1):53-68.
22. Waltenberger J., Claesson-Welsh L., Siegbahn A., et al. Different signal transduction of KDR and Flt1, to receptors for vascular endothelial growth factor. J Biol Chem 1994, 269(43):26988-26995.
23. Salmaggi A., Eoli M., Frigerio S., et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent glioma. J Neurooncol 2003, 62(3):297-303.
24. Moen M. Bevacizumab: in previously treated glioblastoma. Drugs 2010, 70(2):181-189.
25. Gordon M., Margolin K., Talpaz M., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001, 19(3):843-850.
26. Jain R. A new target for tumor therapy. N Engl J Med 2009, 360(25):2669-2671.
27. Kim K., Li B., Houck K., et al. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992, 7(1):53-64.
28. Dickson P., Hamner J., Sims T., et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007, 13(13):3942-3950.
29. Jain R. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Natl Med 2001, 7(9):987-989.
30. Gorski D., Beckett M., Jaskowiak N., et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999, 59(14):3374-3378.
31. United States Food, Drug Administration FDA briefing document oncology drug advisory committee meeting STN 125085/191 and 192 (bevacizumab) 2010, US Department of Health and Human Services, Rockville (MD).
32. Friedman H., Prados M., Wen P.Y., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27(28):4733-4740.
33. Kreisl T., Kim L., Moore K., et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009, 27(5):740-745.
34. Gressett S., Shah S. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 2009, 43(3):490-501.
35. Sugrue M., Purdie D., Feng P., et al. Serious wound healing complications (WHCs) in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV) as part of a first-line regiment: results from the BRITE Observational Cohort Study (OCS). J Clin Oncol 2008, 26(Suppl 15). [abstract: 4105].
36. Macdonald D., Cascino T., Schold S., et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990, 8(7):1277-1280.
37. Kamoun W., Ley C., Farrar C., et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009, 27(15):2542-2552.
38. Silbergeld D., Rostomily R., Alvord E. The cause of death in patients with glioblastoma is multifactorial: clinical factors and autopsy findings in 117 cases of supratentorial glioblastoma in adults. J Neurooncol 1991, 10(2):179-185.
39. Quant E., Wen P. Response assessment in neuro-oncology. Curr Oncol Rep 2011, 13(1):50-56.
40. Wen P., Macdonald D., Reardon D., et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010, 28(11):1963-1972.
41. Thompson E., Dosa E., Kraemer D., et al. Correlation of MRI sequences to assess glioblastoma multiforme treated with bevacizumab. J Neurooncol 2011, 103(2):353-360.
42. Norden A., Drappatz J., Muzikansky A., et al. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol 2009, 92(2):149-155.
43. Reardon D., Fink K., Mikkelsen T., et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008, 26(34):5610-5617.
44. Beal K., Abrey L., Gutin P. Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol 2011, 6:2.
45. de Groot J., Lamborn K., Chang S., et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 2011, 29(19):2689-2695.
46. Platten M., Dorner N., Hofer S., et al. Evaluation of distant spread in bevacizumab-treated versus control-treated patients with malignant gliomas: a matched-pair study. J Clin Oncol 2010, 28(Suppl 15). [abstract: 2064].
47. Khasraw M., Abrey L., Lassman A., et al. Phase II trial of continuous low dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV). J Clin Oncol 2010, 28(Suppl 15). [abstract: 2065].
48. Rubenstein J., Kim J., Ozawa T., et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000, 2(4):306-314.
49. Batchelor T., Duda D., di Tomaso E. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010, 28(17):2817-2823.
50. Riina H., Fraser J., Fralin S., et al. Superselective intra-arterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma. J Exp Ther Oncol 2009, 8(2):145-150.
51. Boockvar J., Tsiouris A., Hofstetter C., et al. Safety and maximum tolerated dose of superselective intra-arterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical trial. J Neurosurg 2011, 114(3):624-632.
52. Vredenburgh J., Desjardins A., Reardon D., et al. Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol 2009, 11(1):80-91.
53. Brandsma D., Stalpers L., Taal W., et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008, 9(5):453-461.
54. Rahman M., Hoh B. Avastin in the treatment for radiation necrosis: exciting results from a recent randomized trial. World Neurosurg 2011, 75(1):4-5.
55. Levin V., Bidaut L., Hou P., et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011, 79(5):1487-1495.